Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Measured Wealth Private Client Group LLC

Measured Wealth Private Client Group LLC raised its position in Bristol-Myers Squibb (NYSE:BMY) by 12.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,336 shares of the biopharmaceutical company’s stock after buying an additional 720 shares during the period. Measured Wealth Private Client Group LLC’s holdings in Bristol-Myers Squibb were worth $325,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. TCG Advisory Services LLC boosted its position in Bristol-Myers Squibb by 99.1% in the 4th quarter. TCG Advisory Services LLC now owns 11,258 shares of the biopharmaceutical company’s stock valued at $578,000 after buying an additional 5,604 shares during the period. AJOVista LLC purchased a new stake in Bristol-Myers Squibb during the 4th quarter worth about $153,000. Sapient Capital LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $2,713,000. Axxcess Wealth Management LLC increased its stake in shares of Bristol-Myers Squibb by 35.0% during the fourth quarter. Axxcess Wealth Management LLC now owns 60,140 shares of the biopharmaceutical company’s stock worth $3,086,000 after buying an additional 15,585 shares during the period. Finally, Los Angeles Capital Management LLC raised its holdings in Bristol-Myers Squibb by 24.5% in the fourth quarter. Los Angeles Capital Management LLC now owns 1,913,249 shares of the biopharmaceutical company’s stock valued at $98,169,000 after acquiring an additional 376,367 shares in the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock traded up $0.29 during trading on Friday, reaching $43.99. The company’s stock had a trading volume of 12,104,489 shares, compared to its average volume of 14,314,010. The business has a 50 day moving average price of $50.37 and a 200-day moving average price of $50.65. The company has a market capitalization of $89.17 billion, a P/E ratio of -14.19, a price-to-earnings-growth ratio of 14.82 and a beta of 0.45. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a 12-month low of $43.33 and a 12-month high of $69.10.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. The business had revenue of $11.87 billion for the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.05 EPS. As a group, sell-side analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 5.46%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Analyst Upgrades and Downgrades

Several research analysts have commented on BMY shares. BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a report on Friday, April 26th. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday, April 15th. Finally, Redburn Atlantic cut shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.